Volume 25, Number 6—June 2019
Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease
|Animal no.||Sex||Group||Clinical illness||Clinical and gross pathology findings†|
||Control ΔG vaccine
||Loss of appetite (d 6–8); labored breathing (d 6–8). Died on d 8.
||Lymphopenia (d 6); serosanguinous nasal and oral discharge (d 8), serosanguinous pleural fluid, severely inflated, enlarged lungs with severe congestion and hemorrhage of all lobes, multifocal to coalescing hemorrhage of the mucosal surface of the urinary bladder.
|F-1||F||F vaccine||None||Thrombocytopenia (d 15); >3 fold increase in ALT (d 6), >3 fold increase in AST|
||Increase in CRP (d 6)
|F/G-1||F||F + G vaccine||None||Increase in CRP (d 8)|
|F/G-2||M||F + G vaccine||None||Thrombocytopenia (d 21, d 28); increase in CRP (d 8, d 10, d 15)|
|F/G-3||M||F + G vaccine||None||Thrombocytopenia (d 8)|
*ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein.
†Lymphopenia is defined as a >30% decrease in number of lymphocytes; thrombocytopenia is defined as a >30% decrease in number of platelets.
1Current affiliation: Mayo Clinic, Rochester, Minnesota, USA.